Seeking Alpha

Prostate cancer screens could improve with gene technology, as firms seek to find an alternative...

Prostate cancer screens could improve with gene technology, as firms seek to find an alternative to the industry standard PSA blood test. Two companies set to capitalize on the $740M market for a better test are Myriad Genetics (MYGN +1.3%) and Genomic Health (GHDX +0.3%), says InvestorPlace.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)